Treatment approaches utilizing retinoic acid to target differentiation have a similar rationale to the proposed targeting of CD49b and have effectively improved survival in patients with neuroblastoma and acute promyelocytic leukemia [9]. The gene discussed is ITGA2; the disease is neuroblastoma.